-
A Breakthrough for Chronic Skin Sensitivity: FDA Approves Rhapsido (remibrutinib)
A New Chapter for Symptomatic Dermographism For those living with symptomatic dermographism, even the slightest touch, scratch, or pressure can lead to uncomfortable, raised, red welts. For years, patients have struggled with the unpredictable nature of this skin condition. Recently, the landscape for treatment has shifted significantly with the FDA approval of Rhapsido (remibrutinib), developed…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-08-2026 TO 02-14-2026
Well well, The Seattle Seahawks take the Win in Super Bowl LX. This is what Google’s Gemini summarized regarding stock market prediction after the Win. And now, back to the BIO-TECH STOCK CATALYST REPORT. We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 01-18-2026 TO 01-24-2026
We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock quote page…
$ABBV, $AZN, $ELDN, $GMAB, $GNLX, $LLY, $LTRN, $MNKD, $NOV, $NVO, $NVS, $PFE, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases